MDSpire - Summary
From the Journals
Feature

EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials

An overview of key visual and anatomic findings with EYP-1901 from the DAVIO 2 and VERONA clinical trials, presented at Macula Society 2026

  • March 24, 2026

  • 6 min

Share

Patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME) often face long-term vision loss despite existing anti-VEGF treatments, largely due to undertreatment and high discontinuation rates. The new EYP-1901 (vorolanib intravitreal insert) offers a multi-mechanistic approach, targeting both angiogenesis and inflammation, and demonstrates promising results in clinical trials for sustained visual stability. With ongoing pivotal trials set to conclude by 2026, EYP-1901 presents a potential solution to the treatment burden impacting patient outcomes.

Original Source(s)

EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials

  • March 24, 2026

Related Content

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Could NPDR Be Treated Orally?

Phase 1b results for danegaptide indicate promising safety profile in patients with non-proliferative diabetic retinopathy and macular edema

  • March 24, 2026

  • 5 min
Why Glaucoma Prevalence Is Rising

... and what the eye care community must do next